Recap: Xencor Q4 Earnings
Recap: Xencor Q4 Earnings
Shares of Xencor (NASDAQ:XNCR) increased in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share rose 48.94% year over year to ($0.24), which beat the estimate of ($0.38).
Revenue of $41,854,000 rose by 1090.39% from the same period last year, which beat the estimate of $29,460,000.
Looking Ahead
Xencor Sees Ending 2021 With $425M-$475M In Cash, Cash Equivalents And Marketable Securities
Details Of The Call
Date: Feb 23, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/c6jkuoa9
Price Action
Company's 52-week high was at $55.33
52-week low: $19.35
Price action over last quarter: Up 27.61%
Company Overview
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. Xencor earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Shares of Xencor (NASDAQ:XNCR) increased in after-market trading after the company reported Q4 results.
的股份Xencor(纳斯达克:XNCR)在该公司公布第四季度业绩后,盘后交易增加。
Quarterly Results
季度业绩
Earnings per share rose 48.94% year over year to ($0.24), which beat the estimate of ($0.38).
每股盈利较上年同期增长48.94%至0.24美元,超过预估的0.38美元。
Revenue of $41,854,000 rose by 1090.39% from the same period last year, which beat the estimate of $29,460,000.
营收为41,854,000美元,比去年同期增长1090.39%,超过了29,46万美元的预期。
Looking Ahead
展望未来
Xencor Sees Ending 2021 With $425M-$475M In Cash, Cash Equivalents And Marketable Securities
Xencor预计2021年底现金、现金等价物和有价证券将达到4.25亿至4.75亿美元
Details Of The Call
通话详情
Date: Feb 23, 2021
日期:2021年2月23日
Time: 04:30 PM
时间:下午4时30分
ET Webcast URL: https://edge.media-server.com/mmc/p/c6jkuoa9
Price Action
价格行动
Company's 52-week high was at $55.33
该公司52周高点为55.33美元
52-week low: $19.35
52周低点:19.35美元
Price action over last quarter: Up 27.61%
上季度价格走势:上涨27.61%
Company Overview
公司概述
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. Xencor earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Xencor Inc是一家总部设在美国的临床阶段生物制药公司。它专注于发现和开发工程单克隆抗体和其他蛋白质疗法,用于治疗严重和危及生命的疾病,但医疗需求尚未得到满足。该公司利用其XmAb技术平台创建了XmAb5871和XmAb7195等候选抗体产品。它的投资组合中也有一些临床前阶段的候选药物,如XmAb14045和XmAb13676。Xencor的收入来自其内部开发的候选药物的研发合作和许可证。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧